^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Melanoma |
| Drug: | CS1002 (ipilimumab biosimilar) (CTLA4 inhibitor) + nofazinlimab (CS1003) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Published date:
12/02/2021
Excerpt:
Of the 5 evaluable pts with MEL in Arm A and 7 in Arm B, ORR was 20.0% (1 PR) and 42.9% (1 CR, 2 PR) respectively. Of the 9 evaluable pts with HCC, ORR was 11% (1 PR)...The combination of CS1002 and CS1003 demonstrated a promising anti-tumor activity and favorable safety profile in pts with pretreated MSI-H/dMMR tumors, anti-PD-(L)1-refractory MEL and anti-PD-(L)1-refractory HCC at two dose levels of CS1002.
Source:
Title:
981P-Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Published date:
09/13/2021
Excerpt:
Of 9 and 7 evaluable pts with MSI-H/dMMR tumors in A and B, objective response rate (ORR) was 44.4% (4 pts had partial response, PR) and 57.1% (1 had complete response and 3 had PR), respectively....The combination of CS1002 and CS1003 demonstrated an acceptable safety profile and showed promising preliminary anti-tumor activity in pts with MSI-H/dMMR tumors and anti-PD-(L)1 refractory melanoma at two dose levels.
Trial ID:
